Skip to main content
. 2018 May 21;12(7):1104–1124. doi: 10.1002/1878-0261.12314

Figure 8.

Figure 8

PTF1a sensitizes PDAC cells to gemcitabine in vivo. (A) Experimental timeline. (B) Immunoblot of PTF1a expression from excised tumors in mice treated ± Dox and ± Gem. (C) RT‐qPCR of tumor samples from the indicated groups for the Tet‐induced PTF1a transgene (TgPTF1a) as well as for endogenous NR5a2,PRSS1, and CPA1 genes. (D) Hematoxylin and eosin (H&E) staining, PRSS2 immunofluorescence (green), and whole‐mount images of tumors isolated from mice treated ± Dox and ± Gem (scale bars = 50 μm for sections; 2.5 mm for whole‐mount images). (E) Tumor weights obtained from Panc‐1 Tet‐PTF1a cells ± Dox and ± Gem (n = 12–14 mice per experimental group). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, N.S., not significant.